Results 41 to 50 of about 30,809 (165)

Age and Vasodilator Response to Different Hyperemic Agents: Adenosine versus Contrast Medium

open access: yesReviews in Cardiovascular Medicine
Background: Age-related remodelling has the potential to affect the microvascular response to hyperemic stimuli. However, its precise effects on the vasodilatory response to adenosine and contrast medium, as well as its influence on fractional flow ...
Domenico Galante   +18 more
doaj   +1 more source

Novel evaluation of pulmonary hypertension associated with chronic lung disease using perfusion SPECT/CT: A pilot study

open access: yesPulmonary Circulation
In pulmonary hypertension (PH) associated with chronic lung disease (CLD), identifying patients who would benefit from pulmonary vasodilators is a significant clinical challenge because the presence of PH is associated with poorer survival.
Kenichiro Atsumi   +7 more
doaj   +1 more source

Antiarrhythmic Properties of Beta Blockers: Focus on Nebivolol

open access: yesInternational Journal of the Cardiovascular Academy
Beta-blockers are commonly used medications for cardiovascular diseases. Beta-blockers are effective antiarrhythmic agents, and they are class 2 agents in the Vaughan-Williams classification.
Bülent Görenek   +7 more
doaj   +1 more source

Acute Digital Ischemia After Arterial Injection of Crushed Zolpidem Tablets: Role of Microcrystalline Cellulose? A Case Report

open access: yesFrontiers in Pharmacology, 2020
Literature is scarce on acute ischemia after intra-arterial injection of crushed tablets and no effective medical treatment against the progression of lesions is reported.
Grégoire Détriché   +16 more
doaj   +1 more source

Seguimento de dois anos em pacientes com hipertensão arterial pulmonar sob tratamento com sildenafila Seguimiento de dos años en pacientes con hipertensión arterial pulmonar bajo tratamiento con sildenafil Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil

open access: yesArquivos Brasileiros de Cardiologia, 2010
FUNDAMENTO: Os efeitos de longo prazo das drogas desenvolvidas para o controle da hipertensão arterial pulmonar (HAP) são pouco conhecidos, já que os estudos multicêntricos em geral têm duração de 12 a 16 semanas.
Sonia Meiken Franchi   +5 more
doaj  

Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

open access: yesPharmaceutics
Interstitial lung diseases (ILDs) encompass a heterogeneous group of over 200 disorders that require individualized treatment. Antifibrotic agents, such as nintedanib and pirfenidone, have remarkably revolutionized the treatment landscape of patients ...
Vito D’Agnano   +8 more
doaj   +1 more source

Comment to: The chemical mediators of some sclerotherapy complications (Les médiateurs chimiques dans certaines complications de la sclérothérapie), by Ferrara F, Ferrara G. Phlébologie 2012;65:27-31.

open access: yesVeins and Lymphatics, 2012
To evaluate the chemical reaction of the venous wall to different sclerosing agents, the Authors studied the level of blood histamine concentration before and 8-10 min after sclerotherapy injection into large 3-6 mm subcutaneous varices.
Alessandro Frullini
doaj   +1 more source

National Institute Pulmonary Hypertension Registry (NIPHeR): Insights from the first pulmonary hypertension registry of Pakistan

open access: yesJournal of the Pakistan Medical Association
Objective: To analyse the characteristics, management and outcomes of patients with pulmonary hypertension from a dedicated registry. Method: The retrospective study was conducted at the Pulmonary Hypertension Clinic of the National Institute of ...
Jawed Abubaker   +5 more
doaj   +1 more source

Vasodepressor Effects of Adenosine in the Cat are Independent of Cyclooxygenase, Potassium Channels, and Nitric Oxide Pathways

open access: yesDrugs in R&D, 2019
Background Pulmonary arterial hypertension is a hemodynamic disorder. Signs and symptoms are generally difficult to recognize because they are non-specific. The current treatment for pulmonary arterial hypertension offers no cure or prevention; therefore,
Alan David Kaye   +4 more
doaj   +1 more source

Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review

open access: yesFrontiers in Oncology
IntroductionImmune Checkpoint Inhibitors (ICIs) may cause various immune- related Adverse Events (irAEs). Of these events, vascular involvement is still considered an uncommon irAEs and generally concerns large or medium vessels.
Valérian Rivet   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy